Company Filing History:
Years Active: 2014-2016
Title: Barbara Richichi: Innovator in Melanoma Immunotherapy
Introduction
Barbara Richichi is a prominent inventor based in Sesto Fiorentino, Italy. She has made significant contributions to the field of immunotherapy, particularly in the development of synthetic glycoconjugates for melanoma treatment. With a total of 2 patents, her work is paving the way for innovative cancer therapies.
Latest Patents
Richichi's latest patents include groundbreaking inventions aimed at improving melanoma immunotherapy. The first patent, titled "Immunogenic synthetic glycoconjugate for the immunotherapy of melanoma," describes a specific antibody against a compound that features a linker suitable for spacing the saccharide moiety and the carrier. This invention is designed to enhance the efficacy of immunogenic molecules in targeting melanoma cells. The second patent, "Synthetic immunogenic glycoconjugate for melanoma immunotherapy," refers to compounds that serve as active ingredients in melanoma vaccines. These compounds are immunogenic artificial antigens that mimic well-known tumor-associated antigens, potentially aiding in the diagnosis and treatment of tumors over-expressing GM3 ganglioside.
Career Highlights
Throughout her career, Barbara Richichi has worked with esteemed organizations such as Azienda Ospedaliero-Universitaria Careggi and Consorzio Interuniversitario Nazionale per la Scienza e Tecnologia dei Materiali. Her experience in these institutions has allowed her to collaborate on various research projects focused on advancing medical science.
Collaborations
Richichi has collaborated with notable colleagues, including Cristina Nativi and Lucio Toma. These partnerships have contributed to her innovative research and the successful development of her patents.
Conclusion
Barbara Richichi's contributions to melanoma immunotherapy through her patents and collaborations highlight her role as a leading inventor in the field. Her work continues to inspire advancements in cancer treatment and research.